| | | Firm | Analyst | | Argus Research Company | Michael Newshel, CFA | | Bank of America Merrill Lynch | Rachel McMinn | | Barclays Capital | Jim Birchenough, MD | | BMO Capital Markets | Jason Zhang PhD | | BWS Financial | Hamed Khorsand | | Citigroup | Yaron Werber MD | | Cowen & Company | Phil Nadeau PhD | | Credit Suisse | Michael Aberman MD | | Deutsche Bank | Mark Schoenebaum | | First Global Stockbroking Ltd. | Devina Mehra | | Goldman Sachs | Davis Bu | | Jefferies & Company | Thomas Wei | | JPMorgan | Geoffrey Meacham PhD | | Lazard Capital Markets | Joel Sendek | | Leerink Swann | Joshua Schimmer MD | | Merriman Curhan Ford | Michael King | | Morgan Joseph | Shiv Kapoor | | Morgan Stanley | Steve Harr | | Needham | Alan Carr | | Oppenheimer | Bret Holley PhD | | RBC Capital Markets | Jason Kantor | | Robert W. Baird & Co | Thomas J. Russo CFA | | Roth Capital | Edward Nash | | Sanford C. Bernstein & Co. | Geoffrey Porges PhD | | Standard and Poors | Steven Silver | | Summer Street Research Partners | Carol Werther | | ThinkEquity | Brian Scorney | | UBS | Maged Shenouda | | Wedbush Pac Grow Lifesciences | Y. Katherine Xu | | Wells Fargo Securities | Aaron Reames | | William Blair & Company | John Sonnier |
|
 |
| Gilead Sciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gilead Sciences's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gilead Sciences or its management. Gilead Sciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
